-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2025-521854-40-00
6
2025-12-22
Intra-Abdominal Candidiasis.
-
2025-522340-40-00
5
2025-12-04
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System
-
2024-516909-23-00
4
2025-10-28
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
-
2024-519743-15-00
5
2025-10-20
Influenza immunisation
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2025-520629-19-00
3
2025-10-01
HIV Infections
-
2024-518811-20-00
4
2025-09-30
Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
-
2025-521115-40-00
4
2025-09-30
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-520322-11-00
4
2025-09-29
Type 2 Diabetes Mellitus (T2D)